Publications
Detailed Information
Efficacy of pembrolizumab monotherapy for advanced gastric/gastroesophageal junction cancer with programmed death ligand 1 combined positive score ≥10 : Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score >= 10
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wainberg, Zev A. | - |
dc.contributor.author | Fuchs, Charles S. | - |
dc.contributor.author | Tabernero, Josep | - |
dc.contributor.author | Shitara, Kohei | - |
dc.contributor.author | Muro, Kei | - |
dc.contributor.author | Van Cutsem, Eric | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Chung, Hyun Cheol | - |
dc.contributor.author | Yamaguchi, Kensei | - |
dc.contributor.author | Varga, Eniko | - |
dc.contributor.author | Chen, Jen-Shi | - |
dc.contributor.author | Hochhauser, Daniel | - |
dc.contributor.author | Thuss-Patience, Peter | - |
dc.contributor.author | Al-Batran, Salah-Eddin | - |
dc.contributor.author | Garrido, Marcelo | - |
dc.contributor.author | Kher, Uma | - |
dc.contributor.author | Shih, Chie-Schin | - |
dc.contributor.author | Shah, Sukrut | - |
dc.contributor.author | Bhagia, Pooja | - |
dc.contributor.author | Chao, Joseph | - |
dc.date.accessioned | 2022-04-18T09:24:25Z | - |
dc.date.available | 2022-04-18T09:24:25Z | - |
dc.date.created | 2021-05-17 | - |
dc.date.created | 2021-05-17 | - |
dc.date.created | 2021-05-17 | - |
dc.date.created | 2021-05-17 | - |
dc.date.created | 2021-05-17 | - |
dc.date.issued | 2021-04-01 | - |
dc.identifier.citation | Clinical Cancer Research, Vol.27 No.7, pp.1923-1931 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.other | 131555 | - |
dc.identifier.uri | https://hdl.handle.net/10371/178103 | - |
dc.description.abstract | Purpose: Pembrolizumab demonstrated efficacy in PD-L1-positive [combined positive score (CPS) >= 1] advanced gastric/gastro-esophageal junction (G/GEJ) cancer in the first-, second-, and third-line setting in KEYNOTE-062, KEYNOTE-061, and KEYNOTE-059, respectively. To better delineate the specificity of CPS as a predictor of dinical outcomes, we analyzed pembrolizumab efficacy in patients with CPS >= 10 in these trials. Patients and Methods: Included were patients with CPS >= 10 tumors from KEYNOTE-059 cohort I (pembrolizumab, n = 46; post hoc), KEYNOTE-061 (pembrolizumab, n = 53; chemotherapy, n = 55; post hoc), and KEYNOTE-062 (pembrolizumab, n = 92; chemotherapy, n = 90; primary). Efficacy outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR). Results: In KEYNOTE-059, median follow-up was 6 months, median OS was 8 months [95% confidence interval (CI), 5.8-11.1], ORR was 17%, and median (range) DOR was 21 months (3+ to 35+). In KEYNOTE-061, median follow-up was 9 months, median OS (pembrolizumab vs. chemotherapy) was 10 versus 8 months (HR, 0.64; 95% CI, 0.41-1.02), median PFS was 3 months versus 3 months (HR, 0.86; 95% CI, 056-1.33), ORR was 25% versus 9%, and median (range) DOR was not reached (4 to 26+ months) versus 7 months (3-7). In KEYNOTE-062, median follow-up was 11 months, median OS (pembrolizumab vs. chemotherapy) was 17 months versus 11 months (HR, 0.69; 95% CI, 0.49-0.97), median PFS was 3 months versus 6 months (HR, 1.09, 95% CI; 0.79-1.49), ORR was 25% versus 38%, and median (range) DOR was 19 months (1+ to 34+) versus 7 months (2+ to 30+). Conclusions: This comprehensive analysis showed consistent improvements toward more favorable clinical outcomes with pembrolizumab across lines of therapy in patients with CPS >= 10 G/GEJ cancer. | - |
dc.language | 영어 | - |
dc.publisher | American Association for Cancer Research | - |
dc.title | Efficacy of pembrolizumab monotherapy for advanced gastric/gastroesophageal junction cancer with programmed death ligand 1 combined positive score ≥10 | - |
dc.title.alternative | Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score >= 10 | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-20-2980 | - |
dc.citation.journaltitle | Clinical Cancer Research | - |
dc.identifier.wosid | 000636977600014 | - |
dc.identifier.scopusid | 2-s2.0-85100918894 | - |
dc.citation.endpage | 1931 | - |
dc.citation.number | 7 | - |
dc.citation.startpage | 1923 | - |
dc.citation.volume | 27 | - |
dc.identifier.sci | 000636977600014 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | PD-L1 EXPRESSION | - |
dc.subject.keywordPlus | GASTRIC-CANCER | - |
dc.subject.keywordPlus | PROGNOSTIC-SIGNIFICANCE | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | NIVOLUMAB | - |
dc.subject.keywordPlus | SURVIVAL | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.